Pricing based on your capital. All-inclusive.
Pricing adjusts to your capital under management, with no à la carte options and no hidden costs. You get all of Redmontis for a clear annual subscription.
Pricing based on capital under management. All of Redmontis, no add-ons, no surprises.
- Runway, cash and burn in real time
- Biotech-native FP&A modeling
- Clinical milestones tied to cash
- Unlimited compared scenarios
- One-click board and investor reporting
- R&D tax credit calculation and funding tracking
- Alerts on critical funding points
- Onboarding support
Excluding tax, per company and per year.
$30,000, compared to the real alternatives.
Price isn't judged on its own, but against what an executive pays today to run their finances, and against the cost of a decision made too late.
- Cheaper than every real alternative, including an Excel maintained by a consultant ($15–30k/year in cumulative time)
- Marginal next to a single bad runway call, which runs into the hundreds of thousands of dollars
- Scenarios in 3 hours, instead of 4 to 6 weeks of manual rebuilding
Sources: outsourced CFO, Pilot (Fractional CFO Cost Guide, 2026); horizontal FP&A tools, Vendr and Limelight (2026); impact of a single decision, 2 to 3 months of burn. 3-hour turnaround: feedback from biotech CEO and CFO users.
See for yourself, on your own numbers.
A 30-minute demo is enough to see whether the time saved justifies the subscription. The decision is yours, with no commitment.
Request a demo